5:46 PM
 | 
Nov 07, 2008
 |  BC Extra  |  Clinical News

Plethora gains after PSD502 meets endpoints

Plethora (LSE:PLE) was up 8.5p (55%) to 24p on Friday after PSD502 met all three co-primary endpoints at week 12 vs. placebo in a Phase III trial to...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >